Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
GLUE Stock Summary
Top 10 Correlated ETFs
GLUE
In the News
GLUE Financial details
Company Rating
Neutral
Market Cap
361.61M
Income
-133.13M
Revenue
0
Book val./share
3.15
Cash/share
4.08
Dividend
-
Dividend %
-
Employees
133
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-2.98
Forward P/E
-
PEG
-1.79
P/S
-
P/B
2.08
P/C
1.44
P/FCF
-3.16
Quick Ratio
7.91
Current Ratio
8.09
Debt / Equity
0.26
LT Debt / Equity
0.24
-
-
EPS (TTM)
-2.59
EPS next Y
-
EPS next Q
-
EPS this Y
18.47%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-17.14%
-
-
-
-
SMA20
-
SMA50
40%
SMA100
133.33%
Inst Own
71.97%
Inst Trans
0.89%
ROA
-51%
ROE
-56%
ROC
-0.61%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.44-8.84
52W High
-26.5%
52W Low
+194%
RSI
42
Rel Volume
0.6
Avg Volume
138.73K
Volume
83.36K
Perf Week
-25.19%
Perf Month
-1.67%
Perf Quarter
135.2%
Perf Half Y
17.6%
-
-
-
-
Beta
1.446
-
-
Volatility
0.55%, 0.62%
Prev Close
-2.97%
Price
5.88
Change
-18.11%
GLUE Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.18 | -0.82 | -1.55 | -2.22 | -2.63 | |
Operating cash flow per share | -0.14 | -0.52 | -1.28 | -1.96 | -0.85 | |
Free cash flow per share | -0.17 | -0.6 | -1.48 | -2.23 | -1.22 | |
Cash per share | 0.14 | 0.95 | 7.44 | 5.57 | 4.52 | |
Book value per share | -0.28 | -1.11 | 7.47 | 5.75 | 3.49 | |
Tangible book value per share | -0.28 | -1.11 | 7.47 | 5.75 | 3.49 | |
Share holders equity per share | -0.28 | -1.11 | 7.47 | 5.75 | 3.49 | |
Interest debt per share | 0.45 | 1.54 | 0 | 1.07 | 0.9 | |
Market cap | 931.98M | 931.98M | 950.26M | 359.4M | 290.39M | |
Enterprise value | 926.73M | 958.04M | 604.19M | 351.49M | 208.33M | |
P/E ratio | -116.25 | -25.84 | -13.21 | -3.44 | -2.15 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -150.98 | -40.43 | -16.01 | -3.89 | -6.63 | |
PFCF ratio | -123.31 | -35.25 | -13.75 | -3.41 | -4.62 | |
P/B Ratio | -76.72 | -19.13 | 2.73 | 1.32 | 1.62 | |
PTB ratio | -76.72 | -19.13 | 2.73 | 1.32 | 1.62 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -121.2 | -35.13 | -8.31 | -3.12 | -1.52 | |
EV to operating cash flow | -150.13 | -41.56 | -10.18 | -3.8 | -4.76 | |
EV to free cash flow | -122.62 | -36.23 | -8.74 | -3.34 | -3.32 | |
Earnings yield | -0.01 | -0.04 | -0.08 | -0.29 | -0.47 | |
Free cash flow yield | -0.01 | -0.03 | -0.07 | -0.29 | -0.22 | |
Debt to equity | -1.62 | -1.39 | 0 | 0.17 | 0.26 | |
Debt to assets | 1.78 | 1.37 | 0 | 0.14 | 0.15 | |
Net debt to EBITDA | 0.69 | -0.96 | 4.76 | 0.07 | 0.6 | |
Current ratio | 2.27 | 1.49 | 20.96 | 10.79 | 5.07 | |
Interest coverage | -7.99K | 0 | 0 | -29.86 | 0 | |
Income quality | 0.8 | 0.64 | 0.8 | 0.85 | 0.32 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.22 | 0.15 | 0.16 | 0.14 | 0.43 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -19.24 | -6.31 | -4.56 | -3.45 | -3.06 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 1.06 | 4.52 | 16.12 | 16.92 | 14.38 | |
ROIC | -1.1 | -1.48 | -0.2 | -0.3 | -0.54 | |
Return on tangible assets | -0.72 | -0.73 | -0.2 | -0.31 | -0.45 | |
Graham Net | -0.39 | -1.28 | 7.03 | 4.19 | 2.11 | |
Working capital | 5.47M | 14.32M | 332.03M | 250.32M | 189.62M | |
Tangible asset value | -12.15M | -48.73M | 347.52M | 271.41M | 179.25M | |
Net current asset value | -13.48M | -54.52M | 329.85M | 204.91M | 111.71M | |
Invested capital | -1.62 | -1.39 | 0 | 0.17 | 0.26 | |
Average receivables | 0 | 0 | 0 | 3.83M | 4.08M | |
Average payables | 0 | 5.13M | 6.81M | 7.21M | 9.51M | |
Average inventory | 0 | 0 | 0 | 480K | 480K | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 16.2K | 4.8K | 1.12K | 335.28 | 654.21 | |
Days of inventory on hand | 0 | 0 | 0 | 40.94 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.02 | 0.08 | 0.33 | 1.09 | 0.56 | |
Inventory turnover | 0 | 0 | 0 | 8.92 | 0 | |
ROE | 0.66 | 0.74 | -0.21 | -0.39 | -0.76 | |
Capex per share | -0.03 | -0.08 | -0.21 | -0.27 | -0.37 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.59 | -0.6 | -0.71 | -0.7 | -0.58 | |
Operating cash flow per share | -0.49 | -0.47 | -0.51 | -0.5 | 0.52 | |
Free cash flow per share | -0.64 | -0.66 | -0.64 | -0.53 | 0.49 | |
Cash per share | 5.38 | 4.7 | 4.11 | 3.58 | 4.08 | |
Book value per share | 5.55 | 4.94 | 4.32 | 3.7 | 3.15 | |
Tangible book value per share | 5.55 | 4.94 | 4.32 | 3.7 | 3.15 | |
Share holders equity per share | 5.55 | 4.94 | 4.32 | 3.7 | 3.15 | |
Interest debt per share | 1 | 0.92 | 0.95 | 0.93 | 0.81 | |
Market cap | 372.08M | 384.42M | 338.61M | 238.61M | 321.64M | |
Enterprise value | 364.17M | 378.73M | 338.62M | 225.96M | 239.58M | |
P/E ratio | -3.2 | -3.22 | -2.41 | -1.71 | -2.42 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -15.53 | -16.42 | -13.37 | -9.66 | 10.85 | |
PFCF ratio | -11.91 | -11.8 | -10.64 | -9.05 | 11.51 | |
P/B Ratio | 1.37 | 1.58 | 1.58 | 1.29 | 1.79 | |
PTB ratio | 1.37 | 1.58 | 1.58 | 1.29 | 1.79 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -11.31 | -11.13 | -9.47 | -6.11 | -7.26 | |
EV to operating cash flow | -15.2 | -16.18 | -13.37 | -9.15 | 8.08 | |
EV to free cash flow | -11.66 | -11.62 | -10.64 | -8.57 | 8.57 | |
Earnings yield | -0.08 | -0.08 | -0.1 | -0.15 | -0.1 | |
Free cash flow yield | -0.08 | -0.08 | -0.09 | -0.11 | 0.09 | |
Debt to equity | 0.17 | 0.19 | 0.22 | 0.25 | 0.26 | |
Debt to assets | 0.14 | 0.15 | 0.17 | 0.18 | 0.15 | |
Net debt to EBITDA | 0.25 | 0.17 | 0 | 0.34 | 2.49 | |
Current ratio | 10.79 | 11.73 | 10.9 | 8.09 | 5.07 | |
Interest coverage | -16.33 | 36.64 | 0 | 0 | 0 | |
Income quality | 0.78 | 0.73 | 0.72 | 0.71 | -0.89 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.3 | 0.39 | 0.26 | 0.07 | -0.06 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -6.8 | -7.98 | -4.68 | -0.9 | -0.91 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 8.62 | 8.19 | 8.32 | 7.64 | 6.43 | |
ROIC | -0.08 | -0.09 | -0.12 | -0.13 | -0.13 | |
Return on tangible assets | -0.08 | -0.1 | -0.13 | -0.14 | -0.11 | |
Graham Net | 4.05 | 3.42 | 2.81 | 2.23 | 1.9 | |
Working capital | 250.32M | 220.04M | 189.02M | 160.3M | 189.62M | |
Tangible asset value | 271.41M | 243.73M | 213.65M | 184.52M | 179.25M | |
Net current asset value | 204.91M | 175.25M | 143.14M | 115.33M | 111.71M | |
Invested capital | 0.17 | 0.19 | 0.22 | 0.25 | 0.26 | |
Average receivables | 12.61M | 4.91M | 1.66M | 724K | 399.5K | |
Average payables | 8.81M | 7.62M | 6.35M | 5.4M | 8.33M | |
Average inventory | 480K | 960K | 480K | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 263.83 | 577.22 | 343.44 | 269.9 | 543.71 | |
Days of inventory on hand | 32.21 | 75.07 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.34 | 0.16 | 0.26 | 0.33 | 0.17 | |
Inventory turnover | 2.79 | 1.2 | 0 | 0 | 0 | |
ROE | -0.11 | -0.12 | -0.16 | -0.19 | -0.19 | |
Capex per share | -0.15 | -0.19 | -0.13 | -0.03 | -0.03 |
GLUE Frequently Asked Questions
What is Monte Rosa Therapeutics, Inc. stock symbol ?
Monte Rosa Therapeutics, Inc. is a US stock , located in Boston of Ma and trading under the symbol GLUE
What is Monte Rosa Therapeutics, Inc. stock quote today ?
Monte Rosa Therapeutics, Inc. stock price is $5.88 today.
Is Monte Rosa Therapeutics, Inc. stock public?
Yes, Monte Rosa Therapeutics, Inc. is a publicly traded company.